Clinical data presentation of KEYTRUDA® (pembrolizumab) in combination with chemotherapy in eligible PD-L1-negative mNSCLC patients

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Could KEYTRUDA in combination with chemotherapy improve treatment expectations for untreated squamous and non-squamous PD-L1 mNSCLC patients?^*†

KEYNOTE-189 clinical data presentation

KEYNOTE-407 clinical data presentation

KEYLearning Hub: Immuno-oncology (IO) treatment in first-line metastatic non-small cell lung carcinoma (mNSCLC) – a focus on KEYTRUDA (pembrolizumab) in patients with a PD-L1 expression of <1% through case studies

A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated adverse events

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

*KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.¹

^†KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.¹

ALK = Anaplastic Lymphoma Kinase; EGFR = Epidermal Growth Factor Receptor; NSCLC = Non-Small Cell Lung Cancer; PD-L1 = Programmed Cell Death Ligand 1.

Find out more information about KEYTRUDA® (pembrolizumab) in metastatic NSCLC:

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website